Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)

Table of Contents

Chapter 1: Executive Summary

Overview

Scope and Methodology

Market Overview and Potential

• Figure 1-1: Global Cell and Gene Therapy Market, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Table 1-1: Global Cell and Gene Therapy Market, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Figure 1-2: Global Share of Cell and Gene Therapy Market, by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Figure 1-3: Global Share of Cell and Gene Therapy Market, by Product Segment, 2029 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]

 

Chapter 2: Introduction to Cell and Gene Therapy

Introduction

• Table 2-1: Total Numbers of Approved Cell, Gene, & RNA Therapies, by Type, 2022-2024, Global (count, %)
• Figure 2-1: Share of Total Global Numbers of Approved Cell, Gene, & RNA Therapies, by Type, January 2025 (%)

Cell Therapy

CAR T

Stem Cells

Adult Stem Cells

Human Embryonic Stem Cells

• Table 2-2: Adult vs. Embryonic Stem Cells

Gene Therapy

• Table 2-3: Somatic vs. Germ Line Gene Therapy

Viral Vector System and New Developments

• Table 2-4: Selected Examples of Viruses in Gene Therapy
• Figure 2-2: Estimated Viral Vector Use in Commercialized Cell and Gene Therapies, by Type, 2022 (%)

Non-viral Systems for Transporting Genes

Gene Editing

Cell and Gene Therapy: Characteristics

• Table 2-5: Cell Therapy vs Gene Therapy

Staffing

Manufacturing Process for CAR-T

Leukapheresis

Activation

Transduction

Expansion

Cell and Gene Therapy Manufacturing Processes

• Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies [current and discontinued therapies]
• Figure 2-3: Manufacturing Process Time for Select Autologous Cell and Gene Therapies [current and discontinued therapies]

Cost

Reimbursement

Logistics

Mergers and Acquisitions

• Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market

Deals, Agreements, and Collaborations

Regulatory Developments

Fast Track

Orphan Drug

Breakthrough Therapy

Accelerated Approval

Priority Review

• Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy, by Select Country

Gene Therapy Approval Process

Pipeline, Development Overview

Pipeline, Development Progress

• Table 2-9: Global Cell, Gene, & RNA Therapy Clinical Trial Growth (pre-clinical I through phase III), 2022-2024 (Count, %)
• Figure 2-4: Global Cell, Gene, & RNA Therapy Development Progress (pre-clinical through phase III), as of Q4 2024
• Table 2-10: Global Gene Therapy Pipeline, by Phase, 2022-2024 (count, %)
• Figure 2-5: Global Gene Therapy Pipeline Shares by Phase, Q4 2024 (%)

Pipeline by Condition and Therapeutic Area

• Table 2-11: Global Cell, Gene, & RNA Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
• Figure 2-6: Global Gene Therapy Pipeline Shares, by Therapeutic Area, Q4 2024 (%) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
• Table 2-12: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
• Table 2-13: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin’s; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne’s muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa; Other]
• Figure 2-7: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease, Share Q4 2024 (%)  [Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin’s; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne’s muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa]
• Table 2-14: Global Non-GM Cell Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, NA/Unspecified]
• Table 2-15: Global Non-GM Cell Therapy Pipeline, by Condition/Disease, 2022-2024 (count, %) [Alzheimer’s disease; Arthritis, osteo; Cancer, brain; Cancer, breast; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lung, non-small cell; Cancer, melanoma; Cancer, ovarian; Cancer, solid, unspecified; Cancer, unspecified; COVID-19 complications; Diabetes, Type 1; Graft-versus-host disease; Heart failure; Hepatic dysfunction, unspecified; Infarction, myocardial; Ischemia, cerebral; Parkinson’s disease; Respiratory distress syndrome, acute; Spinal cord injury]
• Table 2-16: Global Non-GM Cell Therapy Pipeline, by Rare Disease Targeted, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Anal fistula; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lymphoma, non-Hodgkin’s; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Dystrophy, Duchenne’s muscular; Epidermolysis bullosa; Fibrosis, pulmonary, idiopathic; Graft-versus-host disease; Huntington’s disease; Myelodysplastic syndrome; Respiratory distress syndrome, acute; Retinitis pigmentosa; Spinal cord injury; Thalassemia]
• Table 2-17: Global RNA Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Antiparasitic, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous]
• Table 2-18: Global RNA Therapy Pipeline, by Rare Disease Targeted, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Cancer, liver; Cancer, ovarian; Cancer, pancreatic; Cystic fibrosis; Dementia, frontotemporal; Dystrophy, Duchenne’s muscular; Dystrophy, myotonic muscular; Fibrosis, pulmonary, idiopathic; Huntington’s disease; Infection, malaria prophylaxis; Infection, rabies prophylaxis; Primary ciliary dyskinesia; Respiratory distress syndrome, acute]

Phase III Development

• Table 2-19: Phase III Development – Cell and Gene Therapies, Select Projects

End Users

Hospitals

Research

Wound Care Centers

Cancer Centers

 

Chapter 3: Cell and Gene Therapy Markets in Oncology

Overview

Biochemistry of Cancer Cells

Causes of Cancer Growth

Environmental Factors, DNA, RNA

• Table 3-1: Virus Association with Human Cancer

Cellular Oncogenes

Tumor Suppressor Genes

Global Cancer Burden

• Figure 3-1: Estimated Number of New Cancer Cases, Both Sexes, Age 0-85+, All Cancers, 2020 to 2040
• Figure 3-2: Incidence of Cancer, by Type, 2020 [Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid]
• Figure 3-3: Worldwide Distribution of Cancer Incidence, by Type, 2020 [Breast, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Other Cancers]

Market Outlook

• Table 3-2: Cell, Gene, & RNA Therapy Markets in Oncology, 2024-2030 ($ million)
• Figure 3-4: Cell, Gene, & RNA Therapy Markets in Oncology, 2024-2030 ($ million)

Principal Products

Abecma

APCeden

Aucatzyl

Breyanzi

Carvykti

CreaVax-RCC

Delytact

Gendicine

Imlygic

Immuncell-LC

Kymriah

Provenge

Relma-cel

Rytelo

Tecartus

Tecelra

Yescarta

Zevor-cel

• Table 3-3: Cell and Gene Therapy in Oncology

Trends in Research and Development

Phase III Development

• Table 3-4: Select Oncology Phase III Cell, Gene, & RNA Therapy Developments, through March 2025

Market Breakdown of Cell and Gene Therapies

• Table 3-5: Oncology Cell and Gene Therapy Markets, by Product Type, Estimated Sales 2024 and Projected 2030 Sales ($ million) [CAR-T, Cell Immunotherapy, Gene/Oligo/Conjugate Therapy, Other Cell]
• Figure 3-5: Oncology Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [CAR-T, Cell Immunotherapy, Gene Therapy]

Oncology Cell and Gene Therapy Market by Cancer Type

• Table 3-6: Oncology Cell, Gene, & RNA Therapy Market, by Cancer Type, Estimated 2024 and Projected 2030 Sales ($ million) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Undefined Blood Cancer, Other Cancers]
• Table 3-7: Oncology Cell, Gene, & RNA Therapy Market, by General Indication, 2024 (%) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers]
• Figure 3-6: Oncology Cell, Gene, & RNA Therapy Market, by General Indication, 2024 (%) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers]

Regional Market Summary

• Table 3-8: Oncology Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
• Figure 3-7: Oncology Cell and Gene Therapy Market, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
• Figure 3-8: Oncology Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [APAC, Europe, North America, ROW]

Competitor Summary

• Table 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million, %) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
• Figure 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Sales, Estimated 2024 ($ million) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
• Figure 3-10: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Estimated 2024 (%) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]

 

Chapter 4: Cell and Gene Therapy Markets in Neurological-Related Disorders

Overview

Market Outlook

• Table 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2024-2030 ($ million)
• Figure 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2024-2030 ($ million)

Principal Products

Amvuttra

Libmeldy/ Lenmeldy

NeuroNata-R

Onpattro

SKYSONA

Spinraza

Stemirac

Upstaza

Wainua

Zolgensma

• Table 4-2: Cell, Gene, and RNA Therapy in Neurological Diseases and Disorders

Trends in Research and Development

Phase III Development

• Table 4-3: Select Neurological Phase III Cell and Gene Therapy Developments, through January 2025

Market Breakdown of Cell and Gene Therapies

• Table 4-4: Neurological Conditions Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell Therapy, Gene Therapy, RNA/Antisense Therapy]
• Figure 4-2: Neurological Conditions Cell, Gene, & RNA Therapy Market Distribution, by Product Type, 2024 (%) [Cell Therapy, Gene Therapy, RNA/Antisense Therapy]

Regional Market Summary

• Table 4-5: Neurological Conditions Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
• Figure 4-3: Neurological Conditions Cell, Gene, & RNA Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]

Competitor Summary

• Table 4-6: Neurological Conditions Cell and Gene Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million, %) [Alnylam Pharmaceuticals, Biogen, Novartis, Others]
• Figure 4-4: Neurological Conditions Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2024 ($ million) [Alnylam Pharmaceuticals, Biogen, Novartis, Others]

 

Chapter 5: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders

Overview

Market Outlook

• Table 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2024-2030 ($ million)
• Figure 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2024-2030 ($ million)

Principal Products

AlloStem

Amondys

BIO4

Carticel

Cartiform

CartiLife

Cartistem

Chondron

Elevidys

Exondys

JACC

MACI

Ortho-ACI and Ortho-ATI

Ossron

Osteocel and Osteoplus

Spherox

Trinity Elite and Trinity Evolution

Vyondys

• Table 5-2: Cell and Gene Therapies in Musculoskeletal Diseases and Disorders

Trends in Research and Development

Phase III Development

• Table 5-3: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2025

Market Breakdown of Cell and Gene Therapies

• Table 5-4: Musculoskeletal Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million)

Musculoskeletal Cell and Gene Therapy Market by Indication

• Table 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication, Estimated 2024 and Projected 2030 Sales ($ million) [Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD]
• Figure 5-2: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication, Estimated 2024 (%) [Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD]

Regional Market Summary

• Figure 5-3: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region, Estimated 2024 (%) [APAC, Europe, United States, ROW]
• Table 5-6: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region, 2024 and Projected 2030 Sales ($ million) [APAC, Europe, United States, ROW]
• Figure 5-4: Musculoskeletal Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 Sales ($ million) [APAC, Europe, United States, ROW]

Competitor Summary

• Table 5-7: Musculoskeletal Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2024 ($ million) [Sarepta, Vericel, Other Companies]
• Figure 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2024 (%) [Sarepta, Vericel, Other Companies]

 

Chapter 6: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders

Overview

Cardiovascular Disease

Selected Blood Disorders

Market Outlook

• Table 6-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2024-2030 ($ million)
• Figure 6-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2024-2030 ($ million)

Principal Products

Collategene

Hearticellgram

HeartSheet

Leqvio

Neovasculgen

Stempeucel

Zynteglo

• Table 6-2: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders

Phase III Development

• Table 6-3: Select Cardiovascular and Blood Disorder in Phase III Cell and Gene Therapy Developments, through January 2025

Market Breakdown of Cell, Gene, and RNA Therapies

• Table 6-4: Cardiovascular and Blood Disorders Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies]
• Figure 6-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies]

Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication

• Table 6-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by General Indication, Estimated 2024 and Projected 2030 Sales ($ million) [Blood, Cardiac, Hypercholesterolemia, Vascular]

Regional Market Summary

• Table 6-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
• Figure 6-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 Sales ($ million) [APAC, Europe, North America, ROW]
• Figure 6-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [APAC, Europe, North America, ROW]

Competitor Summary

 

Chapter 7: Cell and Gene Therapy Markets in Dermatology

Overview

• Table 7-1: Wound Prevalence, by Type [Skin Ulcers: Pressure Injuries, Venous Statis Ulcers, Diabetic Ulcers and Burns: Outpatient Burns, Hospitalized Burns, and Medically Treated Burns]

Market Outlook

• Table 7-2: Cell and Gene Therapy Markets in Dermatology, 2024-2030 ($ million)
• Figure 7-1: Cell and Gene Therapy Markets in Dermatology, 2024-2030 ($ million)

Principal Products

Adipocel

Apligraf

CureSkin

Dermagraft

Epicel

Grafix

Holoderm

Kaloderm

KeraHeal/KeraHeal-Allo

LaViv

Orcel

Quencell

RECELL

Rosmir

Stempeutics/Cutisera

StrataGraft

Stravix

TransCyte

Vyjuvek

• Table 7-3: Cell and Gene Therapy in Dermatological Diseases and Disorders

Trends in Research and Development

Phase III Development

• Table 7-4: Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2025

Market Breakdown of Cell and Gene Therapies

• Table 7-5: Dermatology Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy]
• Figure 7-2: Dermatology Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy]

Dermatology Cell and Gene Therapy Market by Indication

Regional Market Summary

• Table 7-6: Dermatology Cell and Gene Therapy Market, by Country/Region, Estimated 2024 & Projected 2030 Sales ($ million) [APAC, Europe, North America, ROW]
• Figure 7-3: Dermatology Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
• Figure 7-4: Dermatology Cell and Gene Therapy Market Share, by Geographic Region, 2024 (%) [APAC, Europe, North America, ROW]

Competitor Summary

• Table 7-7: Dermatology Cell and Gene Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million) [Krystal Biotech, Organogenesis, Smith & Nephew (Osiris), Vericel, Other]
• Figure 7-5: Dermatology Cell and Gene Therapy Market Share, by Company, Estimated 2024 (%) [Krystal Biotech, Organogenesis, Smith & Nephew (Osiris), Vericel, Other]

 

Chapter 8: Cell and Gene Therapy Markets in Other Conditions

Overview

Market Outlook

• Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2024-2030 ($ million)
• Table 8-1: Cell and Gene Therapy Markets in Other Conditions, 2024-2030 ($ million)

Principal Products

Alofisel

Cupistem

Givlaari

Glybera

Holoclar

Luxturna

Oxlumo

Rethymic

Ryoncil/ Prochymal/ Temcell

Tryngolza

• Table 8-2: Cell and Gene Therapy in Other Diseases and Disorders

Trends in Research and Development

Market Breakdown of Cell and Gene Therapies

• Table 8-3: Other Conditions Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell-based Gene Therapy; RNA, Antisense Etc.; Stem Cell & Other Cell Therapy; Other Gene Therapy]
• Figure 8-2: Other Conditions Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Cell-based Gene Therapy; RNA, Antisense Etc.; Stem Cell & Other Cell Therapy; Other Gene Therapy]

Regional Market Summary

• Table 8-4: Other Conditions Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [Europe, North America, ROW]
• Figure 8-3: Other Conditions Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [Europe, North America, ROW]
• Figure 8-4: Other Conditions Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [Europe, North America, ROW]

Competitor Summary

 

Chapter 9: Cell and Gene Therapy Market Review

Market Influences

Global Demographics

• Table 9-1: Global Population, 1980-2050 (population in millions)

Aging Population

• Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

Cost Containment

• Table 9-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies

Cell and Gene Therapy and Viral Vector Shortages

Global Market Summary

• Table 9-3: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/non-oncology blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Figure 9-2a: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Figure 9-2b: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Figure 9-3: Cell and Gene Therapy Market, Distribution of Sales by Disease Segment, 2024 [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]

Cell vs. Gene Therapy Markets

• Table 9-4: Cell, Gene, & RNA Therapy Market Summary, by Method, 2024-2030 ($ million)
• Figure 9-4: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method, 2024 (%)
• Figure 9-5: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method, 2029 (%)

Regional Market Overview

• Table 9-5: Cell, Gene, & RNA Therapy Market Summary by Geographical Region, 2024-2030 ($ million) [Europe, North America, ROW]

North America

• Table 9-6: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Table 9-7: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Figure 9-6: U.S. Cell and Gene Therapy Market, Distribution by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Table 9-8: Major Cell and Gene Therapy Product Approvals, FDA

Europe/European Union

• Table 9-9: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Disease Area, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Figure 9-7: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Disease Area, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Figure 9-8: Europe Cell and Gene Therapy Market, Distribution by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Table 9-10: Major Cell and Gene Therapy Approvals by EMA

Other Countries

• Table 9-11: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Figure 9-9: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Figure 9-10: ROW Cell, Gene, & RNA Therapy Market, Distribution by Disease Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Table 9-12: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities

Competitor Ranking in Cell and Gene Therapy Markets

• Table 9-13: Estimated Cell and Gene Therapy Sales by Leading Competitors, 2024 Sales ($ million) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
• Figure 9-11: Estimated Cell and Gene Therapy Sales by Leading Competitors, 2024 Sales ($ million) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
• Figure 9-12: Cell and Gene Therapy Market Share Estimates by Leading Competitors, 2024 (%) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]

 

Chapter 10: Market Participants

Leading Influencers

AlloSource

• Table 10-1: AlloSource Corporate Summary

Company Summary

Products

Alnylam Pharmaceuticals, Inc.

• Table 10-2: Alnylam Pharmaceuticals Corporate Summary

Company Summary

Products

Amgen

• Table 10-3: Amgen Corporate Summary

Company Summary

Products

AnGes Inc.

• Table 10-4: AnGes Corporate Summary

Company Summary

Products

Anterogen Co Ltd.

• Table 10-5: Anterogen Corporate Summary

Company Summary

Products

Atara Biotherapeutics

• Table 10-6: Atara Biotherapeutics Corporate Summary

Company Summary

Products

BioCardia

• Table 10-7: BioCardia Summary

Company Summary

Products

Projects in the pipeline using the CardiAMP system include:

Projects in the pipeline using the CardiALLO system include:

Biogen, Inc.

• Table 10-8: Biogen Corporate Summary

Company Summary

Products

BioMarin Pharmaceuticals

• Table 10-9: BioMarin Pharmaceuticals Corporate Summary

Company Summary

Products

bluebird bio, Inc.

• Table 10-10: bluebird bio Corporate Summary

Company Summary

Products

BrainStorm Cell Therapeutics

• Table 10-11: BrainStorm Cell Therapeutics Corporate Summary

Company Summary

Products

Bristol-Myers Squibb

• Table 10-12: Bristol-Myers Squibb Corporate Summary

Company Summary

Products

Candel Therapeutics

• Table 10-13: Candel Therapeutics Corporate Summary

Company Summary

Products

In the pipeline, the company offers:

Castle Creek Biosciences

• Table 10-14: Castle Creek Corporate Summary

Company Summary

Products

Celyad Oncology

• Table 10-15: Celyad Oncology Corporate Summary

Company Summary

Products

Cook Myosite, Inc

• Table 10-16: Cook Myosite Corporate Summary

Company Summary

Products

Dendreon Pharmaceuticals (Sanpower)

• Table 10-17: Dendreon Corporate Summary

Company Summary

Products

Ferring Pharmaceuticals

• Table 10-18: FerGene Corporate Summary

Company Summary

Products

Gamida Cell Ltd.

• Table 10-19: Gamida Cell Corporate Summary

Company Summary

Products

GenSight Biologics S.A.

• Table 10-20: GenSight Biologics Corporate Summary

Company Summary

Products

Gilead Sciences, Inc.

• Table 10-21: Gilead Sciences Corporate Summary

Company Summary

Products

Other selected indications in the pipeline include:

Gradalis, Inc

• Table 10-22: Gradalis Corporate Summary

Company Summary

Products

Helixmith

• Table 10-23: Helixmith Corporate Summary

Company Summary

Products

Inovio Pharmaceuticals, Inc.

• Table 10-24: Inovio Pharmaceuticals Corporate Summary

Company Summary

Products in the Pipeline

Medeor Therapeutics

• Table 10-25: Medeor Therapeutics Corporate Summary

Company Summary

Products

MEDIPOST Co, Ltd.

• Table 10-26: MEDIPOST Corporate Summary

Company Summary

Products

MeiraGTx

• Table 10-27: MeiraGTx Corporate Summary

Company Summary

Products

Mesoblast Ltd.

• Table 10-28: Mesoblast Corporate Summary

Company Summary

Products

Northwest Biotherapeutics, Inc.

• Table 10-29: Northwest Biotherapeutics Corporate Summary

Company Summary

Products

Novartis AG

• Table 10-30: Novartis Corporate Summary

Company Summary

Products

Other Current Projects

NuVasive Biologics

• Table 10-31: NuVasive Biologics Corporate Summary

Company Summary

Products

Orchard Therapeutics

• Table 10-32: Orchard Therapeutics Corporate Summary

Company Summary

Products

Organogenesis

• Table 10-33: Organogenesis Corporate Summary

Company Summary

Products

Orthofix

• Table 10-34: Orthofix Corporate Summary

Company Summary

Products

Osiris Therapeutics, Inc. (Smith & Nephew)

• Table 10-35: Osiris Corporate Summary

Company Summary

Products

Pharmicell

• Table 10-36: Pharmicell Corporate Summary

Company Summary

Products

Pluristem Therapeutics, Inc.

• Table 10-37: Pluristem Therapeutics Corporate Summary

Company Summary

Products

Sangamo Therapeutics

• Table 10-38: Sangamo Therapeutics Corporate Summary

Company Summary

Products

Sanofi

• Table 10-39: Sanofi Corporate Summary

Company Summary

Sarepta Therapeutics

• Table 10-40: Sarepta Corporate Summary

Company Summary

Products

Sotio a.s.

• Table 10-41: Sotio Corporate Summary

Company Summary

Products

Spark Therapeutics

• Table 10-42: Spark Therapeutics Corporate Summary

Company Summary

Products

Pipeline Projects

uniQure N.V.

• Table 10-43: uniQure Corporate Summary

Company Summary

Products

Vericel Corporation

• Table 10-44: Vericel Corporate Summary

Company Summary

Products